根据综合预测因子分析,接受177(177Lu)转移性抗割礼前列腺癌(mCRPC)的患者的总体存活率显示与癌症和白血病B组(CALGB)预后风险组相关,并接受随后FDA批准的延长生命疗法。 在125名接受前列腺特异性膜抗原(PSMA)-靶向β-发射放射性核素的连续前瞻性临床试验治疗的mCRPC患者中,观察到的177Lu的整体OS中位数为20.7个月。获...
PLUVICTO® lutetium Lu 177 vipivotide tetraxetan 是一款靶向肿瘤细胞表面PSMA(前列腺特异性膜抗原),进而释放放射性镥177(Lutetium-177)杀死肿瘤细胞的RDC核药。 药物由诺华公司开发,2022年获FDA批准上市,用于治疗去势抵抗型前列腺癌(mCRPC)成人患者。 药物国内尚未上市,根据英文名我暂称它为镥鲁177肽(音译无出处...
Pluvicto(lutetium Lu 177 vipivotide tetraxetan)结构式如下: Vipivotide tetraxetan (PSMA-617)可以结合到PSMA上,PSMA在80%以上前列腺癌患者中表达,结合后通过Lu-177放出的β辐射杀伤肿瘤细胞。作为一种放射性疗法,只能在有相关资质的医疗机构使用,在美国,现在有192家符合条件医疗机构。 治疗前,要喝大量的水,以便...
镥( 177 Lu) vipivotide tetraxetan,以品牌名称Pluvicto出售,是一种放射性药物,用于治疗前列腺特异性膜抗原(PSMA) 阳性的转移性去势抵抗性前列腺癌(mCRPC)。镥 ( 177 Lu) vipivotide tetraxetan 是一种靶向放射性配体疗法。 镥(177 Lu)vipivotide tetraxetan 于 2022 年 3 月在美国获批用于医疗用途,并于 202...
Examining laboratory-based VISION eligibility and177Lu-PSMA-617 outcomes in patients with metastatic castration-resistant prostate cancer. e17062#Background:Lutetium-177 prostate-specific membrane antigen (177Lu-PSMA-617) is an FDA-approved therapy for metastatic castration-resistant prostate ... Alireza...
On March 23, 2022, the FDA approved lutetium Lu-177 vipivotide tetraxetan (Pluvicto; Novartis), which is referred to in nuclear medicine literature as 177Lu–prostate-specific membrane antigen–617 (177Lu PSMA-617), for the treatment of PSMA-positive metastatic castration...
EAST HANOVER, N.J., March 23, 2022 -- Novartis announced today that the US Food and Drug Administration (FDA) approved Pluvicto™ (lutetium Lu 177 vipivotide tetraxetan) (formerly referred to as 177Lu-PSMA-617) for the treatment of adult patients with a certain type of advanced cancer...
Treatment with the combination of lutetium Lu 177 vipivotide tetraxetan (Pluvicto; formerly 177Lu-PSMA-617) and enzalutamide (Xtandi) led to an improvement in prostate-specific antigen (PSA) progression-free survival (PSA-PFS) vs enzalutamide alone in patients with metastatic castration-resist...
, March 23, 2022 -- Novartis announced today that the US Food and Drug Administration (FDA) approved Pluvicto™ (lutetium Lu 177 vipivotide tetraxetan) (formerly referred to as 177Lu-PSMA-617) for the treatment of adult patients with a certain type of advanced cancer...
During 177Lu–PSMA therapy, co-administration of ARPI occurred in 10/24 (23.8%) of patients.Conclusions:This study highlights the differences in quality metrics between patients who received 177Lu–PSMA therapy in a real-world practice setting compared to the FDA label for this agent and VISION...